Cemiplimab before and after surgery for early-stage lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if the immunotherapy drug cemiplimab, given before and after surgery, can help treat early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. If you have stage II or IIIA lung cancer that can be surgically removed and your tumor has PD-L1 expression of 50% or more, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have stage II or IIIA non-small cell lung cancer that can be removed with surgery
- Your cancer must have high PD-L1 levels (50% or more) and you have not had any prior treatment
- You must be in good enough health to have surgery, with a performance status of 0 or 1 (fully active or able to do light work)
- You must have adequate bone marrow, liver, and kidney function
- You cannot have certain genetic mutations in your tumor (like EGFR, ALK, RET, or ROS1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests a personalized chemotherapy approach for people with early-stage (stage II–IIIB) non-small cell lung cancer that can be removed with surgery. It uses the tumor's PD-L1 level (a marker that helps the immune system attack cancer) to guide treatment before surgery, aiming to improve outcomes.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.